{
  "prompt": {
    "prompt": "Original Transcript:\n**Dictation: Clinical Interaction – Abnormal Uterine Bleeding**  **Patient Details:**  \n- Name: [Fictional Name] Jane Doe  \n- Age: 36  \n- BMI: 18.9 (weight 52 kg, height 1.65 m)  \n- Gravida: 1, Para: 1 (prior full-term vaginal delivery)  \nLast Menstrual Period (LMP): 2 weeks ago (currently mid-cycle)  \n- Contraception: None currently  **History of Presenting Complaint:**  \nMs. Doe presents with a 4-month history of irregular menstrual bleeding. She reports episodes of heavy bleeding lasting 7–10 days, occurring every 2–3 weeks, with associated fatigue. She denies intermenstrual spotting but admits to occasional cramping. No history of post-coital bleeding. She has not been sexually active in the past year.  **Relevant Medical History:**  \nNo known bleeding disorders or thyroid dysfunction.  \nNo prior gynecological procedures (e.g., hysteroscopy, D&C).  \nNo history of fibroids or endometriosis.  \nNo chronic medical conditions.  **Medications & Allergies:**  \nOccasional ibuprofen for cramps (no regular medications).  \nNo known drug allergies.  **Social History:**  \nNon-smoker, occasional alcohol (1–2 units/week).  \nWorks as a teacher; moderate stress levels reported.  **Examination Findings:**  \n- General appearance: Pale conjunctivae (possible anemia).  \n- Abdomen: Soft, non-tender, no palpable masses.  \n- Speculum exam: Cervix appears normal, no visible lesions.  \n- Bimanual exam: Uterus anteverted, normal size, no adnexal tenderness.  **Notable Omissions (for testing purposes):**  \nNo documented assessment of iron studies or hemoglobin.  \nNo inquiry about family history of gynecological malignancies.  \nNo discussion of prior Pap smear history or HPV vaccination status.  \nPelvic ultrasound not yet performed.  **Impression:**  \nAbnormal uterine bleeding (AUB) in a premenopausal patient—differential includes ovulatory dysfunction (e.g., PCOS, thyroid disorder), endometrial polyp, or early perimenopausal changes.  **Management Plan:**  \n1. **Investigations:**  \n   Full blood count (FBC) to assess for anemia.  \n   TSH and prolactin to evaluate endocrine causes.  \n   Pelvic ultrasound to rule out structural pathology.  \n   (No endometrial biopsy arranged at this stage.)  2. **Symptomatic Relief:**  \n   Trial of tranexamic acid during heavy bleeding.  \n   Consider combined oral contraceptive pill (COCP) for cycle regulation if no contraindications.  3. **Follow-Up:**  \n   Review in 6 weeks with investigation results.  \n   If bleeding worsens or anemia confirmed, escalate to gynecology referral.  **Counseling Provided:**  \nReassured that AUB is common but requires evaluation.  \nAdvised to monitor bleeding patterns and report syncope or severe fatigue.  **Dictated by:** Dr. [Fictional Name] Smith  \n**Date:** [Fictional Date]  --*Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.*\n\n\n\nGuideline Analysis:\n## Analysis Against Guidelines\n\n### Management of Uterine Fibroids.\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Include assessment of hemoglobin and iron studies to evaluate for anemia.  \n   Reason: The guideline emphasizes evaluating for anemia in patients with abnormal uterine bleeding (AUB), as it is a common complication. The note mentions pale conjunctivae but lacks lab confirmation.  \n\n2. **Different management plan** - Consider adding a progestin-releasing intrauterine device (IUD) or GnRH antagonist (e.g., relugolix) as a treatment option, especially if fibroids are confirmed.  \n   Reason: The guideline highlights progestin-releasing IUDs and GnRH antagonists (e.g., relugolix, linzagolix) as effective second-tier treatments for fibroid-related AUB.  \n\n3. **Additional information needed** - Perform a pelvic ultrasound to rule out fibroids or other structural causes of AUB.  \n   Reason: The guideline underscores the importance of identifying fibroids or other structural pathologies (e.g., polyps) as a cause of AUB. The note mentions plans for an ultrasound but does not explicitly state its role in fibroid detection.  \n\n### Somewhat Important Recommendations  \n1. **Improved patient advice** - Discuss fertility implications if fibroids are found, including myomectomy as an option for future pregnancy desires.  \n   Reason: The guideline recommends myomectomy for patients desiring fertility, which should be part of counseling if fibroids are confirmed.  \n\n2. **Additional information needed** - Inquire about family history of gynecological malignancies or fibroids.  \n   Reason: The guideline notes that fibroids have a higher incidence in certain populations (e.g., Black women), and family history may inform risk stratification.  \n\n3. **Different management plan** - If fibroids are confirmed, consider UAE (uterine artery embolization) as a minimally invasive option if the patient does not desire fertility.  \n   Reason: The guideline lists UAE as a viable option for fibroid-related symptoms in patients not seeking pregnancy.  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Document prior Pap smear history and HPV vaccination status.  \n   Reason: While not directly related to fibroid management, this information is relevant for overall gynecological care.  \n\n2. **Improved patient advice** - Provide statistics on the efficacy of tranexamic acid vs. hormonal options for bleeding control.  \n   Reason: The guideline compares treatment efficacies, which could help the patient make an informed choice.  \n\n### Unimportant Recommendations  \n1. **Improved patient advice** - Mention focused ultrasound surgery as a noninvasive option if fibroids are confirmed.  \n   Reason: The guideline lists this as an option, but it is less commonly used and may not be immediately relevant.  \n\n2. **Additional information needed** - Assess ovarian reserve if fibroids are suspected.  \n   Reason: The guideline notes that myomectomy does not affect ovarian reserve, making this lower priority.  \n\n### Summary of Critical Gaps:  \n- Lack of anemia workup (hemoglobin/iron studies).  \n- No explicit consideration of fibroids in differential or ultrasound justification.  \n- Missing discussion of fertility-preserving options (e.g., myomectomy) or second-tier medical therapies (e.g., GnRH antagonists).  \n\n### Key Alignment with Guideline:  \n- Appropriate initial workup (TSH, prolactin, pelvic ultrasound).  \n- Tranexamic acid and COCP are guideline-supported first-line options.  \n- Follow-up plan aligns with stepwise management.  \n\nSuggested revisions would strengthen fibroid-specific evaluation and expand treatment options per the guideline.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 60 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Management of Uterine Fibroids.\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- Ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
    "transcript_length": 2896,
    "analysis_length": 3999,
    "guideline_id": "uptodate-2025-uterine-fibroids-leiomyomas-treatment-overview-uptodate-pdf",
    "guideline_title": "Management of Uterine Fibroids."
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"No documented assessment of iron studies or hemoglobin.\",\n      \"suggestedText\": \"Order full blood count (FBC) and iron studies to evaluate for anemia.\",\n      \"context\": \"Guideline emphasizes evaluating for anemia in AUB patients. Pale conjunctivae noted but needs lab confirmation.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Anemia evaluation in AUB\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Pelvic ultrasound to rule out structural pathology.\",\n      \"suggestedText\": \"Pelvic ultrasound to specifically evaluate for fibroids or other structural causes of AUB.\",\n      \"context\": \"Guideline underscores importance of identifying fibroids as a cause of AUB.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Fibroid detection in AUB\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Consider combined oral contraceptive pill (COCP) for cycle regulation if no contraindications.\",\n      \"suggestedText\": \"Consider progestin-releasing IUD or GnRH antagonists (e.g., relugolix) as additional treatment options if fibroids are confirmed.\",\n      \"context\": \"Guideline highlights these as effective second-tier treatments for fibroid-related AUB.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Second-tier fibroid treatments\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"No inquiry about family history of gynecological malignancies.\",\n      \"suggestedText\": \"Document family history of gynecological malignancies and fibroids.\",\n      \"context\": \"Family history may inform risk stratification for fibroids.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Fibroid risk factors\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"If bleeding worsens or anemia confirmed, escalate to gynecology referral.\",\n      \"suggestedText\": \"If fibroids are confirmed, discuss fertility implications and consider myomectomy for patients desiring future pregnancy or UAE for those who don't.\",\n      \"context\": \"Guideline recommends myomectomy for fertility preservation and UAE as minimally invasive option.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Fibroid treatment options\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"No discussion of prior Pap smear history or HPV vaccination status.\",\n      \"suggestedText\": \"Document prior Pap smear history and HPV vaccination status.\",\n      \"context\": \"Relevant for overall gynecological care though not directly related to fibroids.\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"General gynecological care\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-09T17-14-45",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\n**Dictation: Clinical Interaction – Abnormal Uterine Bleeding**  **Patient Details:**  \\n- Name: [Fictional Name] Jane Doe  \\n- Age: 36  \\n- BMI: 18.9 (weight 52 kg, height 1.65 m)  \\n- Gravida: 1, Para: 1 (prior full-term vaginal delivery)  \\nLast Menstrual Period (LMP): 2 weeks ago (currently mid-cycle)  \\n- Contraception: None currently  **History of Presenting Complaint:**  \\nMs. Doe presents with a 4-month history of irregular menstrual bleeding. She reports episodes of heavy bleeding lasting 7–10 days, occurring every 2–3 weeks, with associated fatigue. She denies intermenstrual spotting but admits to occasional cramping. No history of post-coital bleeding. She has not been sexually active in the past year.  **Relevant Medical History:**  \\nNo known bleeding disorders or thyroid dysfunction.  \\nNo prior gynecological procedures (e.g., hysteroscopy, D&C).  \\nNo history of fibroids or endometriosis.  \\nNo chronic medical conditions.  **Medications & Allergies:**  \\nOccasional ibuprofen for cramps (no regular medications).  \\nNo known drug allergies.  **Social History:**  \\nNon-smoker, occasional alcohol (1–2 units/week).  \\nWorks as a teacher; moderate stress levels reported.  **Examination Findings:**  \\n- General appearance: Pale conjunctivae (possible anemia).  \\n- Abdomen: Soft, non-tender, no palpable masses.  \\n- Speculum exam: Cervix appears normal, no visible lesions.  \\n- Bimanual exam: Uterus anteverted, normal size, no adnexal tenderness.  **Notable Omissions (for testing purposes):**  \\nNo documented assessment of iron studies or hemoglobin.  \\nNo inquiry about family history of gynecological malignancies.  \\nNo discussion of prior Pap smear history or HPV vaccination status.  \\nPelvic ultrasound not yet performed.  **Impression:**  \\nAbnormal uterine bleeding (AUB) in a premenopausal patient—differential includes ovulatory dysfunction (e.g., PCOS, thyroid disorder), endometrial polyp, or early perimenopausal changes.  **Management Plan:**  \\n1. **Investigations:**  \\n   Full blood count (FBC) to assess for anemia.  \\n   TSH and prolactin to evaluate endocrine causes.  \\n   Pelvic ultrasound to rule out structural pathology.  \\n   (No endometrial biopsy arranged at this stage.)  2. **Symptomatic Relief:**  \\n   Trial of tranexamic acid during heavy bleeding.  \\n   Consider combined oral contraceptive pill (COCP) for cycle regulation if no contraindications.  3. **Follow-Up:**  \\n   Review in 6 weeks with investigation results.  \\n   If bleeding worsens or anemia confirmed, escalate to gynecology referral.  **Counseling Provided:**  \\nReassured that AUB is common but requires evaluation.  \\nAdvised to monitor bleeding patterns and report syncope or severe fatigue.  **Dictated by:** Dr. [Fictional Name] Smith  \\n**Date:** [Fictional Date]  --*Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.*\\n\\n\\n\\nGuideline Analysis:\\n## Analysis Against Guidelines\\n\\n### Management of Uterine Fibroids.\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Include assessment of hemoglobin and iron studies to evaluate for anemia.  \\n   Reason: The guideline emphasizes evaluating for anemia in patients with abnormal uterine bleeding (AUB), as it is a common complication. The note mentions pale conjunctivae but lacks lab confirmation.  \\n\\n2. **Different management plan** - Consider adding a progestin-releasing intrauterine device (IUD) or GnRH antagonist (e.g., relugolix) as a treatment option, especially if fibroids are confirmed.  \\n   Reason: The guideline highlights progestin-releasing IUDs and GnRH antagonists (e.g., relugolix, linzagolix) as effective second-tier treatments for fibroid-related AUB.  \\n\\n3. **Additional information needed** - Perform a pelvic ultrasound to rule out fibroids or other structural causes of AUB.  \\n   Reason: The guideline underscores the importance of identifying fibroids or other structural pathologies (e.g., polyps) as a cause of AUB. The note mentions plans for an ultrasound but does not explicitly state its role in fibroid detection.  \\n\\n### Somewhat Important Recommendations  \\n1. **Improved patient advice** - Discuss fertility implications if fibroids are found, including myomectomy as an option for future pregnancy desires.  \\n   Reason: The guideline recommends myomectomy for patients desiring fertility, which should be part of counseling if fibroids are confirmed.  \\n\\n2. **Additional information needed** - Inquire about family history of gynecological malignancies or fibroids.  \\n   Reason: The guideline notes that fibroids have a higher incidence in certain populations (e.g., Black women), and family history may inform risk stratification.  \\n\\n3. **Different management plan** - If fibroids are confirmed, consider UAE (uterine artery embolization) as a minimally invasive option if the patient does not desire fertility.  \\n   Reason: The guideline lists UAE as a viable option for fibroid-related symptoms in patients not seeking pregnancy.  \\n\\n### Less Important Recommendations  \\n1. **Additional information needed** - Document prior Pap smear history and HPV vaccination status.  \\n   Reason: While not directly related to fibroid management, this information is relevant for overall gynecological care.  \\n\\n2. **Improved patient advice** - Provide statistics on the efficacy of tranexamic acid vs. hormonal options for bleeding control.  \\n   Reason: The guideline compares treatment efficacies, which could help the patient make an informed choice.  \\n\\n### Unimportant Recommendations  \\n1. **Improved patient advice** - Mention focused ultrasound surgery as a noninvasive option if fibroids are confirmed.  \\n   Reason: The guideline lists this as an option, but it is less commonly used and may not be immediately relevant.  \\n\\n2. **Additional information needed** - Assess ovarian reserve if fibroids are suspected.  \\n   Reason: The guideline notes that myomectomy does not affect ovarian reserve, making this lower priority.  \\n\\n### Summary of Critical Gaps:  \\n- Lack of anemia workup (hemoglobin/iron studies).  \\n- No explicit consideration of fibroids in differential or ultrasound justification.  \\n- Missing discussion of fertility-preserving options (e.g., myomectomy) or second-tier medical therapies (e.g., GnRH antagonists).  \\n\\n### Key Alignment with Guideline:  \\n- Appropriate initial workup (TSH, prolactin, pelvic ultrasound).  \\n- Tranexamic acid and COCP are guideline-supported first-line options.  \\n- Follow-up plan aligns with stepwise management.  \\n\\nSuggested revisions would strengthen fibroid-specific evaluation and expand treatment options per the guideline.\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 60 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: Management of Uterine Fibroids.\\n\\nPlease extract actionable suggestions from this analysis and format them as specified.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"brief explanation of why this change is suggested\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis\\n- Make suggestions specific and actionable\\n- Ensure original text selections are precise and findable in the transcript\\n- Keep context explanations concise but informative\\n- Prioritize suggestions based on clinical importance\\n- If no specific suggestions can be made, return {\\\"suggestions\\\": []}\",\n  \"transcript_length\": 2896,\n  \"analysis_length\": 3999,\n  \"guideline_id\": \"uptodate-2025-uterine-fibroids-leiomyomas-treatment-overview-uptodate-pdf\",\n  \"guideline_title\": \"Management of Uterine Fibroids.\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"No documented assessment of iron studies or hemoglobin.\",\n      \"suggestedText\": \"Order full blood count (FBC) and iron studies to evaluate for anemia.\",\n      \"context\": \"Guideline emphasizes evaluating for anemia in AUB patients. Pale conjunctivae noted but needs lab confirmation.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Anemia evaluation in AUB\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Pelvic ultrasound to rule out structural pathology.\",\n      \"suggestedText\": \"Pelvic ultrasound to specifically evaluate for fibroids or other structural causes of AUB.\",\n      \"context\": \"Guideline underscores importance of identifying fibroids as a cause of AUB.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Fibroid detection in AUB\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Consider combined oral contraceptive pill (COCP) for cycle regulation if no contraindications.\",\n      \"suggestedText\": \"Consider progestin-releasing IUD or GnRH antagonists (e.g., relugolix) as additional treatment options if fibroids are confirmed.\",\n      \"context\": \"Guideline highlights these as effective second-tier treatments for fibroid-related AUB.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Second-tier fibroid treatments\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"No inquiry about family history of gynecological malignancies.\",\n      \"suggestedText\": \"Document family history of gynecological malignancies and fibroids.\",\n      \"context\": \"Family history may inform risk stratification for fibroids.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Fibroid risk factors\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"If bleeding worsens or anemia confirmed, escalate to gynecology referral.\",\n      \"suggestedText\": \"If fibroids are confirmed, discuss fertility implications and consider myomectomy for patients desiring future pregnancy or UAE for those who don't.\",\n      \"context\": \"Guideline recommends myomectomy for fertility preservation and UAE as minimally invasive option.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Fibroid treatment options\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"No discussion of prior Pap smear history or HPV vaccination status.\",\n      \"suggestedText\": \"Document prior Pap smear history and HPV vaccination status.\",\n      \"context\": \"Relevant for overall gynecological care though not directly related to fibroids.\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"General gynecological care\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 1823\nCompletion tokens: 640\nTotal tokens: 2463\nEstimated cost: $0.001231",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 1823,
    "completion_tokens": 640,
    "total_tokens": 2463,
    "estimated_cost_usd": 0.0012315
  }
}